Drugs / LM-364
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07847905 | Oct 2026 → Oct 2030 expected | — | LaNova Medicines Limited | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07694765 | Jul 2026 → Dec 2028 expected | cancer | LaNova Medicines Limited | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM-364 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07847905 ↗ |
| Route | Intravenous | “Q3W, Intravenous Drip” NCT07694765 ↗ |